Vivance

Executive Summary

Vivance (formerly AWAK Technologies) is a Singapore-based med-tech company developing a next-generation peritoneal dialysis platform. Its wearable device, on-site dialysate generation, and AI-driven remote monitoring aim to reduce therapy burden and improve quality of life for chronic kidney disease patients. With $20M raised and preclinical-stage status, Vivance addresses a significant unmet need in home dialysis, targeting improved patient autonomy and clinical outcomes. The company’s innovative approach could disrupt the traditional peritoneal dialysis market, which is dominated by large players, by offering a more portable and automated solution. Vivance’s technology has potential to reduce hospitalization rates and healthcare costs, positioning it as a compelling investment opportunity in the nephrology space. However, as a preclinical-stage company, Vivance faces execution risks including regulatory hurdles, clinical validation, and manufacturing scale-up. Its success hinges on advancing through preclinical studies and securing regulatory approvals (e.g., CE mark or FDA IDE) to initiate human trials. The competitive landscape includes Baxter and Fresenius, but Vivance’s differentiated wearable design may carve a niche. Near-term catalysts include completion of key preclinical studies, regulatory submissions, and potential strategic partnerships. The company’s cash runway from its $20M raise likely supports operations through 2026, but additional funding will be needed for clinical trials. Given the early stage, conviction is moderate, with a score of 65.

Upcoming Catalysts (preview)

• Q4 2026Completion of pivotal preclinical study for wearable dialysis device60% success
• Q1 2027Regulatory submission for CE mark or FDA IDE50% success
• Q2 2026Series B funding round to support clinical trials70% success